**Patient criteria for those 18 and older**

- Able to receive treatment within 10 days of onset of COVID-19 symptoms.
- Is **NOT**: hospitalized, requiring oxygen due to COVID-19 or experiencing an increase in baseline oxygen from a prior non-COVID-19 condition.
- And meets at least **ONE** of these criteria:
  - 65 or older
  - BMI of 25 or higher
  - Chronic kidney disease
  - Diabetes
  - Weakened immune system from a condition like HIV, AIDS, rheumatoid arthritis, lupus, type 1 diabetes, cancer or asthma
  - Receiving immunosuppressive therapy, such as treatment for cancer or an autoimmune condition
  - Has cardiovascular disease, hypertension or COPD/chronic respiratory disease
  - Pregnant
  - Sickle Cell Anemia
  - Medical Related Technology Dependence such as tracheostomy, gastrostomy, or positive pressure ventilation

**Patient criteria for those less than 18 years of age**

- Consultation with a Pediatric Infectious Disease Specialist is strongly recommended as data on the use of monoclonal antibodies in this age group is limited. Able to receive treatment within 10 days of onset of COVID-19 symptoms.
- Is **NOT**: hospitalized, requiring oxygen due to COVID-19 or experiencing an increase in baseline oxygen from a prior non-COVID-19 condition.
- And meets **at least one** of these criteria:
  - Body mass index (BMI) is greater than the 85th percentile for age and gender
  - Sickle cell disease
  - Congenital or acquired heart disease
  - Neurodevelopmental disease, such as cerebral palsy
  - A medical-related technological dependence, such as tracheostomy, gastrostomy or positive pressure ventilation
  - Asthma, reactive airway disease or other chronic respiratory disease requiring daily medications for control
  - Pregnant
  - Immunosuppression (Immunodeficiency related to a disease process or current immunosuppressive therapy)

*Currently only bamlanivimab/etesevimab is authorized for use in individuals less than 12 years of age/less than 88 pounds.

All age eligible unvaccinated patients who qualify and receive monoclonal antibody therapy should be advised to receive the COVID-19 vaccine 90 days after the monoclonal antibody administration.

Visit Alabama’s COVID-19 Dashboard Hub (arcg.is/0brSGj) and select the “Monoclonal Antibody Therapy Locations” tab to view a map of sites in Alabama that have received at least one shipment of COVID-19 monoclonal antibody therapy. You can also call the HHS Monoclonal Antibodies Call Center at 1-877-332-6585. Most locations require a physician referral, registration, or appointment. Please do not go to a facility without an appointment or a referral.